Protein nanospheres: synergistic nanoplatform-based probes for multimodality imaging

No single clinical imaging modality has the ability to provide both high resolution and high sensitivity at the anatomical, functional and molecular level. Synergistically integrated detection techniques overcome these barriers by combining the advantages of different imaging modalities while reducing their disadvantages. We report the development of protein nanospheres optimized for enhancing MRI, CT and US contrast while also providing high sensitivity optical detection. Transferrin protein nanospheres (TfpNS), silicon coated, doped rare earth oxide and rhodamine B isothiocyanate nanoparticles, Si⊂Gd2O3:Eu,RBITC, (NP) and transferrin protein nanospheres encapsulating Si⊂Gd2O3:Eu,RBITC nanoparticles (TfpNS-NP) were prepared in tissue-mimicking phantoms and imaged utilizing multiple cross-sectional imaging modalities. Preliminary results indicate a 1:1 NP to TfpNS ratio in TfpNS-NP and improved sensitivity of detection for MRI, CT, US and fluorescence imaging relative to its component parts and/or many commercially available contrast agents.

[1]  T. Varghese,et al.  Tissue-Mimicking Oil-in-Gelatin Dispersions for Use in Heterogeneous Elastography Phantoms , 2003, Ultrasonic imaging.

[2]  Jean-Luc Coll,et al.  Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethylene glycol) coatings. , 2009, Small.

[3]  Algirdas Avizienis,et al.  Position Paper , 1994, EDCC.

[4]  Kemin Wang,et al.  Bionanotechnology based on silica nanoparticles , 2004, Medicinal research reviews.

[5]  Sophie Laurent,et al.  Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.

[6]  John V Frangioni,et al.  New technologies for human cancer imaging. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jinwoo Cheon,et al.  Synergistically Integrated Nanoparticles as Multimodal Probes for Nanobiotechnology , 2009 .

[8]  Peter R Seevinck,et al.  Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents. , 2007, Anti-cancer agents in medicinal chemistry.

[9]  N. Serkova,et al.  Toxicity of MRI and CT contrast agents. , 2009, Expert opinion on drug metabolism & toxicology.

[10]  W. Rooney,et al.  Determination of the MRI contrast agent concentration time course in vivo following bolus injection: Effect of equilibrium transcytolemmal water exchange , 2000, Magnetic resonance in medicine.

[11]  R. Pereiro,et al.  Nanoparticles as fluorescent labels for optical imaging and sensing in genomics and proteomics , 2011, Analytical and bioanalytical chemistry.

[12]  Kai Chen,et al.  PET/NIRF/MRI triple functional iron oxide nanoparticles. , 2010, Biomaterials.

[13]  M. Seemann,et al.  Whole-Body PET/MRI: The Future in Oncological Imaging , 2005, Technology in cancer research & treatment.

[14]  M. N. Maisey,et al.  Synergistic imaging , 2004, European Journal of Nuclear Medicine.

[15]  Adam de la Zerda,et al.  Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. , 2010, Nano letters.

[16]  H. Thomsen,et al.  Gadolinium-containing contrast media for radiographic examinations: a position paper , 2002, European Radiology.

[17]  M. Prokop,et al.  Contrast agents in X-ray computed tomography and its applications in oncology. , 2007, Anti-cancer agents in medicinal chemistry.

[18]  P. Perriat,et al.  Multi-luminescent hybrid gadolinium oxide nanoparticles as potential cell labeling. , 2009, Journal of nanoscience and nanotechnology.

[19]  Nicholas J Long,et al.  'Two is better than one'--probes for dual-modality molecular imaging. , 2009, Chemical communications.

[20]  John C Rasmussen,et al.  Molecular imaging with optics: primer and case for near-infrared fluorescence techniques in personalized medicine. , 2008, Journal of biomedical optics.

[21]  Seulki Lee,et al.  Dual-Modality Probes for in Vivo Molecular Imaging , 2009, Molecular imaging.

[22]  Hisataka Kobayashi,et al.  Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. , 2011, Accounts of chemical research.

[23]  Peter Caravan,et al.  Protein binding to lanthanide(III) complexes can reduce the water exchange rate at the lanthanide. , 2007, Inorganic chemistry.

[24]  D. Sparks,et al.  A position paper , 2007, Journal of Molecular Neuroscience.

[25]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[26]  Shuming Nie,et al.  Engineering Luminescent Quantum Dots for In Vivo Molecular and Cellular Imaging , 2006, Annals of Biomedical Engineering.

[27]  Acoustic fingerprints of dye-labeled protein submicrosphere photoacoustic contrast agents. , 2009, Journal of biomedical optics.

[28]  C. Kremser,et al.  Albumin-based nanoparticles as magnetic resonance contrast agents: II. Physicochemical characterisation of purified and standardised nanoparticles , 2010, Histochemistry and Cell Biology.

[29]  Weibo Cai,et al.  Nanoplatforms for targeted molecular imaging in living subjects. , 2007, Small.

[30]  R. MacGillivray,et al.  Intrinsic fluorescence reports a global conformational change in the N-lobe of human serum transferrin following iron release. , 2007, Biochemistry.

[31]  Anne L. Plant,et al.  Transferrin protein nanospheres: a nanoplatform for receptor-mediated cancer cell labeling and gene delivery , 2010, BiOS.

[32]  É. Tóth,et al.  From monomers to micelles: investigation of the parameters influencing proton relaxivity , 2002, JBIC Journal of Biological Inorganic Chemistry.